高等学校化学学报 ›› 2024, Vol. 45 ›› Issue (7): 20240124.doi: 10.7503/cjcu20240124

• 有机化学 • 上一篇    下一篇

含(杂)芳磺酰基哌嗪的蛇床子素衍生物的合成及抗菌活性

杨家强(), 吴学姣, 卢子聪, 陈阳密, 佘慧娴, 刘讴灵   

  1. 遵义医科大学药学院, 遵义 563000
  • 收稿日期:2024-03-18 出版日期:2024-07-10 发布日期:2024-05-13
  • 通讯作者: 杨家强 E-mail:yjqcn@126.com
  • 基金资助:
    贵州省科技计划项目(批准号: 黔科合基础-ZK[2024]一般265)和国家级大学生创新创业训练计划项目(202310661006)

Synthesis and Antibacterial Activities of Osthole Derivatives Containing (Hetero)arylsulfonylpiperazine

YANG Jiaqiang(), WU Xuejiao, LU Zicong, CHEN Yangmi, SHE Huixian, LIU Ouling   

  1. School of Pharmacy,Zunyi Medical University,Zunyi 563000,China
  • Received:2024-03-18 Online:2024-07-10 Published:2024-05-13
  • Contact: YANG Jiaqiang E-mail:yjqcn@126.com
  • Supported by:
    the Science and Technology Plan Project of Guizhou Province, China(No.Qiankehe Foundation ZK[2024]265) and the National College Students’ Innovation and Entrepreneurship Training Program of China(202310661006)

摘要:

设计合成了25个含(杂)芳磺酰基哌嗪的蛇床子素衍生物, 经核磁共振波谱(1H NMR和13C NMR)及元素分析确证了其结构. 抗菌活性测试结果表明, 化合物4q对金黄色葡萄球菌(S. aureus)、 大肠杆菌(E. coli) 耐甲氧西林金黄色葡萄球菌(MRSA)和耐氟喹诺酮大肠杆菌(FREC)的最小抑菌浓度(MIC)分别为0.5, 1, 2和 2 μg/mL, 化合物4s对S. aureus, E. coli, MRSA和FREC的MIC分别为0.25, 0.5, 1和2 μg/mL, 化合物4u对 S. aureus, E. coli, MRSA和FREC的MIC分别为0.5, 2, 1和4 μg/mL, 3个化合物的抗S. aureu活性与对照药苯唑西林相似, 且优于诺氟沙星; 抗E. coli, MRSA和FREC活性优于对照药苯唑西林和诺氟沙星. 研究结果表明, (杂)芳磺酰基哌嗪的引入能有效提高抗菌活性, 扩大抗菌谱.

关键词: 蛇床子素衍生物, 哌嗪, 磺酰胺, 抗菌活性

Abstract:

In order to obtain antibacterial candidate compounds, the strategy of pharmacophore hybridisation was adopted to optimize the structure of the previously obtained active compound. Twenty-five osthole derivatives were designed and synthesized, and confirmed by means of nuclear magnetic resonance hydrogen spectroscopy (1H NMR), nuclear magnetic resonance carbon spectroscopy(13C NMR) and elemental analysis. The antibacterial activities against S. aureusE. coli, methicillin-resistant S. aureus(MRSA) and fluoroquinolone-resistant E. coli(FREC) were evaluated, the results showed that the minimum inhibitory concentration(MIC) of compound 4q was 0.5, 1, 2, 2 μg/mL respectively, the MIC of compound 4s was 0.25, 0.5, 1, 2 μg/mL respectively, and the MIC of compound 4u was 0.5, 2, 1, 4 μg/mL respectively. The inhibitory activities of these compounds against S. aureus were comparable to the control drug oxacillin, and superior to norfloxacin, and against E. coli, MRSA, and FREC were superior to the control drugs oxacillin and norfloxacin. The combination of (hetero)arylsulfonylpiperazine and osthole can effectively enhance antibacterial activities and expand the antibacterial spectrums.

Key words: Osthole derivative, Piperazine, Sulfonamide, Antibacterial activity

中图分类号: 

TrendMD: